Author: Charmaine Fraser

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, recently provided a brief update in-line with its End of Year results via Investor Meet Company and has updated its website with the presentation.   The presentation and Q&A from the meeting are now available at the Company’s website: https://www.physiomics.co.uk/portfolio-item/investor-presentation-full-year-results-and-company-update/       Enquiries:   Physiomics plc Dr Jim Millen, Non-Executive...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the official launch of its Biostatistics offering and expansion of its Data Science and Bioinformatics services.   Leveraging its existing expertise and capabilities across the core Modelling and Simulation service line, the Company is moving forward to expand its offering into...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce its audited results for its financial year ended 30 June 2024.   Click here to read in full....

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it expects to release its audited results for the financial year ended 30 June 2024 during the last week of September 2024.   Dr Peter Sargent (CEO) and Dr Jim Millen (Non-Executive Chairman) will provide a live presentation relating to...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a new contract by an existing, large pharma client. The project involves updating two models previously created for the client with newly generated clinical data. These models are based on the Company’s proprietary Virtual...

Unless otherwise defined herein, the capitalised terms used in this announcement have the same meaning as those used in the Company’s announcements released on 3 July 2024.     Physiomics plc, (AIM: PYC), is pleased to announce, further to the announcements on 3 July 2024, the completion of the WRAP Retail Offer, at the same issue price as the previously announced Placing (together, the “Fundraise”). The WRAP Retail...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has completed a placing, conditional on Admission, of, in aggregate, approximately £381,417 (gross) from the issue of 63,569,573 new ordinary shares of £0.004 each (the “Placing Shares”) at an issue price of £0.006 per Placing Share (the...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE...